Rickets
MONDO:0005520Bone softening and weakening usually caused by deficiency or impaired metabolism of vitamin D. Deficiency of calcium, magnesium, or phosphorus may also cause rickets. It predominantly affects children who suffer from severe malnutrition. It manifests with bone pain, fractures, muscle weakness, and skeletal deformities.
Also known as: rachitis, rickets, rickets (disease), vitamin D hydroxylation-deficient rickets, active rickets, hypovitaminosis D, nutritional rickets, vitamin D deficiency disease
41 clinical trials for this condition and its sub-types, 10 tagged with Rickets itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Rickets
-
Hypophosphatemic rickets 3 trials · 19 incl. sub-types
1 sub-type
- Hereditary hypophosphatemic rickets 1 trial · 18 incl. sub-types Sub-types →
-
Renal osteodystrophy 12 trials
-
Hypocalcemic rickets 0 trials · 3 incl. sub-types
2 sub-types
- Vitamin D-dependent rickets, type 1 0 trials · 3 incl. sub-types Sub-types →
- Vitamin D-dependent rickets, type 2 0 trials Sub-types →
-
Vitamin D-dependent rickets 0 trials · 3 incl. sub-types
3 sub-types
- Vitamin D-dependent rickets, type 1 0 trials · 3 incl. sub-types Sub-types →
- Vitamin D-dependent rickets, type 2 0 trials Sub-types →
- Vitamin D-dependent rickets, type 3 0 trials
Most studied deeper sub-types
-
Dialysis upgrade could protect bones in kidney patients
Disease control OngoingThis study tests whether a newer type of dialysis filter (medium cut-off membrane) can better manage bone and mineral problems common in people with end-stage kidney disease. Thirty adults on maintenance dialysis will try both the new and standard filters for three months each. R…
Sponsor: Gazi University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a replacement enzyme keep calcium buildup in check?
Disease control OngoingThis trial tests the long-term safety of a drug called INZ-701 in people with rare genetic conditions that cause abnormal calcium buildup in the body. The study enrolls people who have already received INZ-701 in an earlier trial and want to continue treatment. Researchers will m…
Phase 2 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for babies: drug targets rare genetic disorder that hardens arteries
Disease control OngoingThis study tests a new medicine called INZ-701 in babies up to 1 year old who have a rare genetic condition (ENPP1 deficiency) that causes severe hardening of the arteries and bone problems. The goal is to see if the drug can raise a key substance in the blood, improve survival, …
Phase 3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for babies with rare calcification disease: first drug trial launches
Disease control OngoingThis study tests a new drug called INZ-701 in up to 16 infants (up to 1 year old) with rare genetic conditions (ENPP1 or ABCC6 deficiency) that cause dangerous calcium buildup in arteries and other problems. The main goal is to check the drug's safety and how the body handles it,…
Phase 1 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Vitamin d may tweak brain waves in depressed women
Symptom relief By invitation onlyThis study looks at whether giving vitamin D supplements to women with depression and low vitamin D levels can change their brain waves. Researchers will measure brain activity using a non-invasive EEG scan before and after supplementation. The trial includes 34 women aged 20-40 …
Sponsor: Bangladesh Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
XLH study: watching the disease, not curing it
Knowledge-focused OngoingThis observational study follows 782 people with X-linked hypophosphatemia (XLH), a rare genetic bone disease, to understand how the condition changes over time. It also monitors the long-term safety and effectiveness of the drug burosumab. No new treatment is given; participants…
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
New study aims to unlock XLH mysteries in adults
Knowledge-focused CancelledThis study will follow 100 adults with X-linked hypophosphatemia (XLH) who are already taking burosumab. Researchers want to see how phosphate levels change over time and how they relate to bone health and overall disease burden. The goal is to better understand the condition and…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Dialysis patients: new markers could predict heart and bone risks
Knowledge-focused OngoingThis study looks at 475 people on hemodialysis to find better markers for bone disease and blood vessel hardening. Researchers are checking if new markers can predict heart attacks, strokes, and death better than current tests. The goal is to improve monitoring and care for dialy…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can personalized nutrition slow kidney decline? new study investigates
Knowledge-focused By invitation onlyThis study follows 1,800 adults with reduced kidney function (not on dialysis) to see how nutrition and lifestyle affect their health. Researchers will track changes in kidney function, heart health, bone health, and thinking skills over time. The goal is to find better ways to m…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
XLH patients observed for a decade to uncover disease secrets
Knowledge-focused OngoingThis study follows 226 people with X-linked hypophosphatemia (XLH) for up to 10 years. Researchers will collect data on height, walking ability, fractures, and overall health to better understand how the disease progresses and affects daily life. No new treatment is being tested;…
Sponsor: Kyowa Kirin Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:22 UTC